February 6, 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – USFDA warning letter

Dear Sir/Madam,

This disclosure is in furtherance of our communication dated February 4, 2026, and in continuation of our earlier disclosures dated August 13, 2025, September 18, 2025, and October 26, 2025, pertaining to the warning letter received following the U.S. FDA inspection of the Company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) at Nacharam, Hyderabad, conducted from August 4, 2025 to August 12, 2025.

The details required to be submitted in form A, pursuant to Regulation 30(13) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), read with SEBI Circular dated February 25, 2025, on Industry Standards Forum, is annexed herewith.

This is for your information and record.

I the undersigned, state and declare that the information and details provided in Form A, in compliance with Regulation 30(13) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is true, correct and complete to the best of my knowledge and belief.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

HIMANSHU AGARWAL
Digitally signed by HIMANSHU AGARWAL
Date: 2026.02.06 17:42:30 +05'30'

Himanshu Agarwal
Whole-time Director and Chief Financial Officer
(DIN: 06672915)

Encl: as above

Form A

Disclosure by Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Regulation 30(13) – Disclosure of communication from regulatory, statutory, enforcement or judicial authority

S. No.	Particulars	Details
1	Name of the listed company	Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)
2	Type of communication received	Warning letter
3	Date of receipt of communication	February 4, 2026
4	Authority from whom communication received	United States Food and Drug Administration (US FDA)
5	Brief summary of the material contents of the communication received, including reasons for receipt of the communication	The US FDA conducted an inspection at the Company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from August 4, 2025 to August 12, 2025. Following the inspection, a Form FDA-483 containing six observations was issued by the US FDA. Based on these observations, the USFDA classified the facility as "Official Action Indicated (OAI)" and subsequently issued a Warning Letter for the said facility.
6	Period for which communication would be applicable, if stated	The Company is required to respond to the Warning Letter within the stipulated timelines prescribed by the US FDA and continues to engage with the regulator thereafter.
7	Expected financial implications on the listed company, if any	The US revenues from this facility contributed less than 2% of consolidated revenues in FY25, with related EBITDA contribution below 1%.
8	Details of any aberrations/non-compliances identified by the authority in the communication	The Warning Letter pertains to observations noted during the inspection, and the Company is undertaking corrective and preventive actions in accordance with regulatory requirements.
9	Details of any penalty or restriction or sanction imposed pursuant to the communication	Nil
10	Action(s) taken by listed company with respect to the communication	The Company is engaging proactively with the USFDA taking corrective and preventive actions and preparing a comprehensive response to be submitted to the agency within the stipulated timeframe. We remain committed to maintain the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.
11	Any other relevant information	Nil

HIMANSHU AGARWAL
Digitally signed by HIMANSHU AGARWAL
Date: 2026.02.06 17:43:02 +05'30'